API

Event: 1395

Key Event Title

?

Liver Cancer

Short name

?

Liver Cancer

Key Event Component

?

Process Object Action

Key Event Overview


AOPs Including This Key Event

?

AOP Name Role of event in AOP
Chronic Cyp2E1 Activation Leading to Liver Cancer AdverseOutcome

Stressors

?



Level of Biological Organization

?

Biological Organization
Organ


Organ term

?



Taxonomic Applicability

?



Life Stages

?



Sex Applicability

?



How This Key Event Works

?


Liver cancer is among the most common forms of cancer and the second leading cause of cancer death. It is more prevalent in males than females; however, prevalence has been increasing in both genders over the last two decades (Ellison, L.F., Wilkins, K. 2012). Hepatocellular carcinoma (HCC) is a primary cancer of the hepatocytes that is typically a progression from the benign hepatocellular adenoma (HCA). The most common risk factor for developing hepatocellular carcinoma is chronic liver injury and inflammation (caused by persistent infection, fatty liver disease, or chemical exposure). This disease is almost always lethal in the absence of extreme intervention measures (e.g., surgery, liver transplant).


How It Is Measured or Detected

?


  • In animal models, the presence of HCA and HCC are measured histologically following the two-year rodent bioassay, which is conducted according to OECD Test Guideline 451 (OECD 2009).
  • In humans, liver cancer is detected by abdominal CT scan followed by biopsy and pathological examination. Symptoms of liver cancer include: jaundice, abdominal pain, nausea, and liver dysfunction. Liver cancer is more common in patients with risk factors that include: viral hepatitis, non-viral hepatitis, chronic alcoholism, obesity leading to steatohepatitis, cirrhosis, and liver fluke infection (Bonder and Afdhal 2012, Paradis 2013, Venkatesh, et al. 2014).

Evidence Supporting Taxonomic Applicability

?


Hepatocellular carcinoma occurs in many vertebrate species including birds, fish, and mammals such as humans.


Regulatory Examples Using This Adverse Outcome

?



References

?


Bonder, A., Afdhal, N., 2012. Evaluation of liver lesions. Clin. Liver Dis. 16, 271-283.

Ellison, L.F., Wilkins, K., 2012. Canadian Trends in Cancer Prevalence. Health Reports 23.

OECD, 2009. OECD Guideline for the Testing of Chemicals: Carcinogenicity Studies (Test Guideline 451).

Paradis, V., 2013. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 190, 21-32.

Venkatesh, S.K., Chandan, V., Roberts, L.R., 2014. Liver masses: a clinical, radiologic, and pathologic perspective. Clin. Gastroenterol. Hepatol. 12, 1414-1429.